LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The FluMist vaccine, manufactured by AstraZeneca, had previously been approved back in 2003 to be given by health care ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

The FDA has started a review of an extension to the labelling for AstraZeneca’s influenza ... FluMist could become the first self-administered flu vaccine in the US, opening up a new avenue ...

(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

More than one in two Irish parents say their child missed schools days in the past year due to flu or flu-like symptoms with ...

In a first, the US Food and Drug Administration on Friday approved a nasal spray flu vaccine for self-administration. Starting next fall, AstraZeneca's FluMist, which was authorized in 2003 to be ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007 ... FluMist is officially the first ...

Andrew Berens gave his rating based on several factors, including AstraZeneca’s strong financial performance in the third quarter of 2024. The company reported total revenues of $13.565 billion, ...